Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement